Inhibrx Biosciences, Inc.

Verified identity

Start with the filing record

The identity and ticker come from the SEC’s official company ticker mapping. Market and editorial coverage are not inferred from that record.

Ticker: INBX
CIK: 0002007919
Exchange: Nasdaq
Universe updated: 2026-08-22

Open SEC filings

Market price

Latest quoteOpens Google

TickerGrove coverage

Latest on Inhibrx Biosciences, Inc.

Companies

Inhibrx reports higher response rate with INBRX-106 combination in Phase 2 HexAgon study

The company reported a 48.3% confirmed objective response rate versus 26.5% for pembrolizumab alone and plans to expand the randomized study in HPV-positive disease.

Published 09-08-2026 · Inhibrx Biosciences Form 8-K — Items 7.01 / 8.01 / 9.01

Research foundation

Read the filing with the right frame

Company analysis

Revenue, EPS and guidance answer different earnings questions

Revenue is the top-line amount recognized from a company’s activities under its accounting policy.

Earnings reading room →

Company analysis

The three financial statements describe one business from different angles

The income statement records revenue and expenses over a period.

Company research desk →

Investing basics

Stocks, ETFs and indexes are different objects

A stock is an ownership interest in one company.

Company research desk →